Recent setbacks for the movement signal a potential turning point for the vaccine makers as the market picks up
Get 2 months free with an annual subscription at
was
€65.88
now
€54.
Transparency is key if public fears about vaccines are to be allayed
Vaccine businesses seen as valuable parts of pharma groups but government hostility could deter future developments
2025 has been a good year for immunisation science, but not in the US
The loss of robust evidence in the public realm harms us all
For as long as there have been vaccines, there has been passionate opposition to them
The decline in funding for vaccinations poses a worldwide threat
